XPO1 and triple-negative breast carcinoma: Based on a previous report indicating that in triple-negative breast cancer cells the inhibition of XPO1 by selinexor was able to repress BIRC5/survivin gene transcription by inhibiting STAT3 acetylation and blocking STAT3 binding to the survivin promoter [20], we assessed STAT3 protein expression and acetylation in LS-BZ-1 cells.